PMC:7408073 / 82527-82922 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T460","span":{"begin":21,"end":27},"obj":"Body_part"},{"id":"T461","span":{"begin":357,"end":360},"obj":"Body_part"}],"attributes":[{"id":"A460","pred":"fma_id","subj":"T460","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A461","pred":"fma_id","subj":"T461","obj":"http://purl.org/sig/ont/fma/fma13443"},{"id":"A462","pred":"fma_id","subj":"T461","obj":"http://purl.org/sig/ont/fma/fma68615"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2887","span":{"begin":55,"end":63},"obj":"Species"},{"id":"2888","span":{"begin":70,"end":80},"obj":"Species"},{"id":"2889","span":{"begin":195,"end":203},"obj":"Species"},{"id":"2898","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"2899","span":{"begin":186,"end":194},"obj":"Disease"}],"attributes":[{"id":"A2887","pred":"tao:has_database_id","subj":"2887","obj":"Tax:9606"},{"id":"A2888","pred":"tao:has_database_id","subj":"2888","obj":"Tax:2697049"},{"id":"A2889","pred":"tao:has_database_id","subj":"2889","obj":"Tax:9606"},{"id":"A2898","pred":"tao:has_database_id","subj":"2898","obj":"MESH:C000657245"},{"id":"A2899","pred":"tao:has_database_id","subj":"2899","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T462","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"T463","span":{"begin":70,"end":78},"obj":"Disease"},{"id":"T464","span":{"begin":70,"end":74},"obj":"Disease"},{"id":"T465","span":{"begin":186,"end":194},"obj":"Disease"},{"id":"T466","span":{"begin":349,"end":353},"obj":"Disease"}],"attributes":[{"id":"A462","pred":"mondo_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A463","pred":"mondo_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A464","pred":"mondo_id","subj":"T464","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A465","pred":"mondo_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A466","pred":"mondo_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T994","span":{"begin":21,"end":27},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T995","span":{"begin":114,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T996","span":{"begin":135,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T997","span":{"begin":245,"end":248},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T63956","span":{"begin":354,"end":356},"obj":"Chemical"}],"attributes":[{"id":"A96164","pred":"chebi_id","subj":"T63956","obj":"http://purl.obolibrary.org/obo/CHEBI_27638"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"LitCovid-sentences","denotations":[{"id":"T406","span":{"begin":0,"end":395},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}

{"project":"2_test","denotations":[{"id":"32708755-32065055-20678966","span":{"begin":205,"end":207},"obj":"32065055"},{"id":"32708755-32366817-20678967","span":{"begin":208,"end":210},"obj":"32366817"},{"id":"32708755-32404477-20678968","span":{"begin":211,"end":213},"obj":"32404477"},{"id":"32708755-32253318-20678969","span":{"begin":217,"end":219},"obj":"32253318"},{"id":"32708755-32243945-20678970","span":{"begin":220,"end":222},"obj":"32243945"},{"id":"32708755-32505227-20678971","span":{"begin":223,"end":226},"obj":"32505227"}],"text":"Actually, the use of plasma from convalescent COVID-19 patients or of SARS-CoV-2-specific neutralizing antibodies has been shown to be a promising option for the treatment of critically COVID-19 patients [32,33,34,35,36,37,172,173]; however, it has some limitations that might be overcome by vaccine strategies or by the production of specific anti SARS-Co-V-2 therapeutic monoclonal antibodies."}